Nose-to-Brain Drug Delivery and Device Selection

Key delivery targets, transport mechanisms and device considerations for nose to brain CNS delivery, from formulation to regulatory submission.

October 1st 2025

15:00 (BST) / 10:00 (ET)

View Linkedin Event

OVERVIEW

Unlock the potential of nasal drug delivery for Central Nervous System (CNS) therapies in this expert-led webinar. With increasing focus on non-invasive routes and the promise of direct nose-to-brain transport, the nasal pathway presents both exciting opportunities and complex challenges. We’ll explore the strategic considerations behind developing drug products for CNS delivery via nasal routes—focusing especially on the critical role of device selection. Attendees will learn how spray pattern, droplet size, and dosing precision can significantly affect drug deposition within the nasal cavity and influence therapeutic effectiveness, particularly in targeting the olfactory region.

The discussion will delve into the importance of harmonising formulation properties with device capabilities to improve bioavailability, stability, and patient adherence. Whether dealing with liquid or dry powder formulations, understanding the nuances of device compatibility is key to overcoming physiological barriers like the blood-brain barrier. We’ll present strategies that integrate formulation science with engineering insights to create viable, efficient nasal dosage forms. Practical device testing methodologies will be examined highlighting how these tools generate data to support robust regulatory submissions and product development decisions.

You’ll gain a comprehensive understanding of the benefits and challenges of Nose-to-Brain (N2B) delivery, including key delivery targets and transport mechanisms. The session will provide a clear view of how smart device selection, paired with tailored formulation development approaches, can unlock more consistent and effective CNS delivery outcomes. Join us to discover how to accelerate your nasal drug development pathway from pre-clinical to market.

Addressed Challenges

01Aligning formulation properties with device capabilities to achieve reliable and consistent drug deposition within the olfactory region of the nasal cavity.

02Overcoming the blood-brain barrier, which blocks the majority of therapeutic molecules from reaching CNS targets despite adequate systemic exposure.

03Selecting between liquid and dry powder dosage forms while balancing stability, mucociliary clearance, dose reproducibility, and device compatibility.

04Generating spray pattern, plume geometry, and delivered dose data that meets regulatory expectations for nasal CNS development and market submissions.

05Designing nasal devices that can be used correctly and consistently by CNS patients who may present with motor impairments or reduced cognitive function.

WHAT YOU WILL LEARN

01Understand the barriers and opportunities of nose-to-brain delivery, including the olfactory and trigeminal transport pathways that bypass systemic circulation.

02Learn how spray pattern, droplet size, and dosing precision influence drug deposition and why device selection is critical to CNS delivery outcomes.

03Explore the formulation considerations for liquid versus dry powder nasal dosage forms and how each affects bioavailability, stability, and patient use.

04Gain practical insight into device testing methodologies including AINI, and how the data generated supports robust regulatory submissions for nasal products.

05Understand how to sequence nasal CNS development activities from pre-clinical feasibility through to clinical manufacture and market readiness.

Reserve Your Seat

First Name

Last Name

Business Email

Job Title

Company

Telephone

Country

Pharma Consent

I accept the Privacy Policy and consent to receiving updates from Pharma D-mand.

Partner Consent

I agree to share my details with Coriolis Pharma for educational follow-up.

SPEAKERS

Dr. Richard Johnson

Chief Scientific Officer & Founder, Upperton Pharma Solutions

Dr Richard Johnson is the Founding Director and Chief Scientific Officer at Upperton Pharma Solutions, a UK-based Contract, Development and Manufacturing Organisation (CDMO) and graduated from Warwick University with a PhD Biochemistry. In 1994 he was part of a management buy-out team that founded Andaris Ltd, a research and development company exploiting the use of spray drying technology in the fields of diagnostic imaging and drug delivery. In 1999, Dr Johnson founded Upperton and has overseen significant growth and expansion over the past 25 years, specialising in spray drying and nasal drug development.

Lara Penn

Senior Development Scientist II, Upperton Pharma Solutions

Lara Penn is a Senior Development Scientist II at Upperton Pharma Solutions in Nottingham. She holds a BSc in Pharmaceutical Chemistry from the University of Leicester. With over five years of experience, Lara has progressed from Quality Control Scientist to senior roles in formulation and project development. She specialises in analytical testing, method validation, and formulation development of oral solid dosage forms. Lara applies a science-led approach to support efficient development and manufacturing under GMP. She is skilled in HPLC, UV-Vis, FTIR, dissolution testing, and preparing technical documentation and SOPs.

Explore Our Services

Turn Registrants Into Relationships

Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.

By ticking this box, you consent to receiving communications from Upperton related to this topic and other products or services within their portfolio;